RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
“Subsequently, PI3K catalytic subunit p110 can form a complete active PI3K enzyme [53] (Fig.”
BackgroundRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
“We observe multiple hits downstream of the driver mutations in all three MAPK pathway mutants (Figure 4B), including selective PI3K dependency in the KRAS mutant background, consistent with KRAS activation of the PI3K/AKT pathway (Boj et al., 2015; Castellano and Downward , 2011).”
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
“PIP3 can then activate amultitude of proteins that include RACGEFs, PDK1, and the AKT1/2/3 serine– threonine kinases.”
BackgroundInfluentialBiological response of cancer cells to radiation treatment
Baskar, R., Dai, J., Wenlong, N., Yeo, R., & Yeoh, K.-W. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00024 · Cited by 638
“…radiation therapy has been driven by constant technological advances (Thariat et al., 2013) with the understanding of various molecular mechanisms involved in the treatment sensitivity and resistance (Jacinto and Hall, 2003; Camphausen and Tofilon, 2004; Sabatini, 2006; Kuwahara et al., 2014).”
BackgroundOncogenic KRAS signalling in pancreatic cancer
Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504
“EFFECTOR PATHWAYS OF ONCOGENIC KRAS KRAS signalling is highly complex and dynamic, engaging various downstream effectors, such as canonical Raf/Mek/Erk, phosphatidylinositol 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase-1 (Pdk1)/Akt, RalGDS/p38MAPK, Rac and Rho, Rassf1, NF1, p120GAP and PLC-e (Castellano…”
BackgroundThe pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review
Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497
“PI3K/RAS interaction has been shown to be indispensable for maintaining cancer cell survival and proliferation [17].”
BackgroundL-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling
Ivetic, A., Hoskins Green, H. L., & Hart, S. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01068 · Cited by 469
“The catalytic activity of PI3K is significantly enhanced in the presence of activated Ras, resulting in increased local pools of PIP3 production (248, 249).”
BackgroundSignaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
“The ability of oncogenic mutants of Ras to transform cells depends, at least in part, on their ability to activate p110α (53, 85).”
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 400
Classes of phosphoinositide 3-kinases at a glance
Jean, S., & Kiger, A. A. (2014) · Journal of Cell Science · doi:10.1242/jcs.093773 · Cited by 379
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
“PI3Ks are a family of heterodimeric lipid kinases composed of catalytic and regulatory subunits that, on stimulation, catalyze production of the second messenger phosphatidylinositol3,4,5-triphosphate (PIP3), which activates downstream kinases, such as PDK1 and AKT (Castellano and Downward, 2011; Bader et al., 2005).”
BackgroundInfluentialRas Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Clark, M. R., Mandal, M., Ochiai, K., & Singh, H. (2014) · Nature Reviews Immunology · doi:10.1038/nri3570 · Cited by 346
Kinsler, V. A., Thomas, A. C., Ishida, M., Bulstrode, N. W., Loughlin, S., Hing, S., Chalker, J., McKenzie, K., Abu-Amero, S., Slater, O., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.70 · Cited by 348
“E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s NRAS is an extensively characterised oncogene involved in the control of key cell signaling pathways (Castellano and Downward, 2011; Pylayeva-Gupta et al., 2011).”
InfluentialDevelopment of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A., & de Bono, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 329
Synaptic plasticity in depression: Molecular, cellular and functional correlates
Marsden, W. N. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.012 · Cited by 317
Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling
Wang, Z. (2021) · Cells · doi:10.3390/cells10123327 · Cited by 287
“EGFR stimulates PI3K either by binding to its p85 subunit directly or indirectly by activating Ras [74,75] (Figure 5B).”
BackgroundOncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Athuluri-Divakar, S. K., Vasquez-Del Carpio, R., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L., Hart, J. R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.045 · Cited by 277
“…mice that harbor an activating mutation in the K-Ras gene, an impressive 95% reduction in lung tumor formation was observed, suggesting that targeting RAS-RBD interactions might constitute an excellent strategy to inhibit oncogenic RAS signaling (Castellano and Downward, 2011; Gupta et al., 2007).”
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
Zhao, H.-F., Wang, J., Shao, W., Wu, C.-P., Chen, Z.-P., To, S.-S. T., & Li, W.-P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0670-3 · Cited by 251
“Ras is capable of interacting with the catalytic isoforms of PI3K to activate PI3K/Akt pathway, while it also serves as a small G-protein to activate MAPK pathway [114].”
BackgroundAKT and ERK dual inhibitors: The way forward?
Cao, Z., Liao, Q., Su, M., Huang, K., Jin, J., & Cao, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.025 · Cited by 234
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
The KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 219
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
Regulation of mTORC2 Signaling
Fu, W., & Hall, M. N. (2020) · Genes · doi:10.3390/genes11091045 · Cited by 213
Ras and Rap1: A tale of two GTPases
Shah, S., Brock, E. J., Ji, K., & Mattingly, R. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 211
Ellis, B. C., Graham, L. D., & Molloy, P. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.10.016 · Cited by 210
“Any discrepancies in results from the two cell lines might be attributed to differences in their mutation status for PI3K/MAPK pathways: HCT116 is mutated in PI3K and KRAS, and HT29 is mutated in PI3K and BRAF [30–32] (see Fig.”
BackgroundSalminen, A., Kaarniranta, K., & Kauppinen, A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.003 · Cited by 209
Liu, Q., & Xie, L. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 203
GTP-Dependent K-Ras Dimerization
Muratcioglu, S., Chavan, T. S., Freed, B. C., Jang, H., Khavrutskii, L., Freed, R. N., Dyba, M. A., Stefanisko, K., Tarasov, S. G., Gursoy, A., et al. (2015) · Structure · doi:10.1016/j.str.2015.04.019 · Cited by 202
“Ras-Effector Binding and Tetramerization Comparison of crystal structures of Ras with its effectors (Raf, PI3K and RalGDS) show that the predicted major β-sheet extension dimer interface (Figure 7A) overlaps the effectors’ binding site.”
BackgroundInfluentialOncogenes in Cell Survival and Cell Death
Shortt, J., & Johnstone, R. W. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009829 · Cited by 193
“GTP-bound RAS binds and activates a range of effector proteins, most notably PI3K (p110) and RAF (Castellano and Downward 2010).”
BackgroundInfluentialNami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 190
KRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 187
“The requirement of PI3K in tumor maintenance is further supported by recent studies in GEMMs showing that Kras-driven lung adenocarcinoma growth is halted by disruption of PI3K interaction with RAS or inducible p110a deletion in advanced tumors (Castellano et al., 2013).”
BackgroundThe Hallmarks of Flavonoids in Cancer
Ponte, L. G. S., Pavan, I. C. B., Mancini, M. C. S., da Silva, L. G. S., Morelli, A. P., Severino, M. B., Bezerra, R. M. N., & Simabuco, F. M. (2021) · Molecules · doi:10.3390/molecules26072029 · Cited by 180
Protein-Thiol Oxidation and Cell Death: Regulatory Role of Glutaredoxins
Allen, E. M. G., & Mieyal, J. J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4644 · Cited by 171
“Ras is a small GTPase that is important for signal transduction and the regulation of cell proliferation, differentiation, and apoptosis (9).”
Cytoskeletal Remodeling in Cancer
Aseervatham, J. (2020) · Biology · doi:10.3390/biology9110385 · Cited by 167
Knight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
Lee, S., Meier, R., Furuta, S., Lenburg, M. E., Kenny, P. A., Xu, R., & Bissell, M. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60498 · Cited by 159
“This interaction of FAM83A with c-Raf and PI3K suggests strongly that FAM83A interacts with Ras, because Ras binding to c-Raf and PI3K is essential for its role in mitogenic/oncogenic signal transduction (38, 40, 41) and Ras binding is essential for c-Raf activation (38, 41).”
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
Gudipaty, S. A., Conner, C. M., Rosenblatt, J., & Montell, D. J. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060748 · Cited by 165
“…in K-Ras, HRas, or NRas not only increase autophagy, as described above, but also can upregulate survival signaling by constitutively activating PI3K/AKT signaling (Castellano & Downward 2011), upregulating antiapoptotic Bcl-XL (Rosen et al. 2000), or downregulating caspase-2 (Yoo et al. 2011).”
BackgroundMorkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
“One of these is the PIK3CA-AKT-mTOR axis, which regulates protein translation and cell survival [5].”
BackgroundPutting the pH into phosphatidic acid signaling
Shin, J. J. H., & Loewen, C. J. R. (2011) · BMC Biology · doi:10.1186/1741-7007-9-85 · Cited by 164
“In mammalian cells, PLD is a potent regulator of the Ras signaling pathway, which is strongly implicated in cancer and well known to regulate cell proliferation, differen tiation and apoptosis [10,11].”
BackgroundTargeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
Cheng, H., Shcherba, M., Pendurti, G., Liang, Y., Piperdi, B., & Perez-Soler, R. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.72 · Cited by 156
Geyer, F. C., Li, A., Papanastasiou, A. D., Smith, A. E., Selenica, P., Burke, K. A., Edelweiss, M., Wen, H., Piscuoglio, S., Schultheis, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04128-5 · Cited by 146
Sugiyama, M. G., Fairn, G. D., & Antonescu, C. N. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00070 · Cited by 137
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 135
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 132
Dou, Z., Pan, J.-A., Dbouk, H. A., Ballou, L. M., DeLeon, J. L., Fan, Y., Chen, J.-S., Liang, Z., Li, G., Backer, J. M., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.022 · Cited by 131
“Unlike other p110s, whose activities are regulated by Ras (Castellano and Downward, 2011), p110b catalytic activity does not seem to be modulated by Ras (Kurosu and Katada, 2001).”
BackgroundThe PI3K, Metabolic, and Autophagy Networks: Interactive Partners in Cellular Health and Disease
Shanware, N. P., Bray, K., & Abraham, R. T. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134717 · Cited by 130
Zhou, F., Li, M., Wei, Y., Lin, K., Lu, Y., Shen, J., Johanning, G. L., & Wang‐Johanning, F. (2016) · Oncotarget · doi:10.18632/oncotarget.11455 · Cited by 139
“Ras genes are among the most frequently mutated proto-oncogenes in cancer, and Ras proteins (K-Ras, H-Ras, and N-Ras) are known to regulate a number of processes that govern cancer progression, including cell proliferation, transformation, differentiation, and survival [23, 24].”
BackgroundNew Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
Genomic alterations in thyroid cancer: biological and clinical insights
Landa, I., & Cabanillas, M. E. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00920-6 · Cited by 154
“As discussed earlier, PI3K signalling has a role in the initiation of a subset of follicular-patterned thyroid tumours via mutations in PTEN , and PI3K activation can be achieved by RAS gene mutations 86 .”
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 142
The genomics and genetics of endometrial cancer
Bell, D. W., & Ohara (2012) · Advances in Genomics and Genetics · doi:10.2147/agg.s28953 · Cited by 151
“73 Somatic mutations in KRAS were first described in EC over two decades ago, and were subsequently found to be significantly more frequent in EEC than in serous EC.”
Sabine, V. S., Crozier, C., Brookes, C. L., Drake, C., Piper, T., van de Velde, C. J. �., Hasenburg, A., Kieback, D., Markopoulos, C. J., Dirix, L. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8272 · Cited by 136
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 138
Self-citationFell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00382 · Cited by 120
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.014 · Cited by 119
Animal models of colorectal cancer
Johnson, R. L., & Fleet, J. C. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9404-6 · Cited by 144
“These mutations activate PI3K activity and elevate levels of its second messenger, phosphatidylinositol-3,4,5triphosphate (PIP3), an activator of Akt kinase [26].”
BackgroundRole of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake
Świderska, E., Strycharz, J., Wróblewski, A. M., Szemraj, J., Drzewoski, J., & Śliwińska, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80402 · Cited by 159
ST6GAL1: A key player in cancer (Review)
Garnham, R., Scott, E., Livermore, K. E., & Munkley, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10458 · Cited by 163
“As outlined previously, ST6GAL1 can regulate PI3K/AKT signalling, a known RAS effector cascade (16,57).”
BackgroundGadgeel, S. M., & Wozniak, A. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.12.001 · Cited by 121
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
Deng, S., Leong, H. C., Datta, A., Gopal, V., Kumar, A. P., & Yap, C. T. (2022) · Cancers · doi:10.3390/cancers14071652 · Cited by 134
Amarante-Mendes, G. P., Rana, A., Datoguia, T. S., Hamerschlak, N., & Brumatti, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010215 · Cited by 138
“It is important to note that RAS can also contribute to the activation of the pro-survival PI3K/AKT/mTOR pathway [20].”
BackgroundPressing the right buttons: signaling in lymphangiogenesis
Coso, S., Bovay, E., & Petrova, T. V. (2014) · Blood · doi:10.1182/blood-2013-12-297317 · Cited by 115
Irvine, M., Stewart, A., Pedersen, B., Boyd, S., Kefford, R., & Rizos, H. (2018) · Oncogenesis · doi:10.1038/s41389-018-0081-3 · Cited by 107
Epithelial-Myoepithelial Carcinoma
Hallani, S. E., Udager, A. M., Bell, D., Fonseca, I., Thompson, L. D. �., Assaad, A. M., Agaimy, A., Luvison, A., Miller, C., Seethala, R. R., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000933 · Cited by 108
“Age (mean [range]) (y) 66 (19-87) Anatomic site (n [%])”
Riquelme, E. M., Behrens, C., Lin, H. Y., Simon, G. R., Papadimitrakopoulou, V. A., Izzo, J. G., Moran, C. A., Kalhor, N., Lee, J. J., Minna, J. D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1141 · Cited by 122
“The PI3K/AKT signaling pathways are frequently activated by oncogenic KRAS deregulating the control of metabolism, proliferation, and apoptosis (23-25).”
The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway
Zoi, V., Kyritsis, A. P., Galani, V., Lazari, D. M., Sioka, C., Voulgaris, S., & Alexiou, G. Α. (2024) · Cancers · doi:10.3390/cancers16081554 · Cited by 124
“…signaling in tumors caused primarily by mutations in RAS or overexpression of RTKs has been linked to increased PI3K activation [47]. constitutively activated RAS signaling in tumors caused primarily by mutations in RAS or overexpression of RTKs has been linked to increased PI3K activation [47].”
BackgroundTargeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 118
“The negative auto-regulation within the PI3K pathway and redundancy with the MAPK and LKB1/AMPK pathways has likely evolved to ensure proper homeostatic control of cell growth in response to mitogenic signals and to prevent unwanted cell growth under specific cellular states, such as low energy conditions [104, 105].”
BackgroundOncogenic KRAS: Signaling and Drug Resistance
Kim, H. J., Lee, H. N., Jeong, M. S., & Jang, S. B. (2021) · Cancers · doi:10.3390/cancers13225599 · Cited by 119
“Activation of ERK kinases plays a role in Ras-induced cellular responses and translocation to the nucleus [21].”
BackgroundInfluentialZdżalik-Bielecka, D., Poświata, A., Kozik, K., Jastrzębski, K., Schink, K. O., Brewińska‐Olchowik, M., Piwocka, K., Stenmark, H., & Miączyńska, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024596118 · Cited by 115
Development of cellular signaling pathway inhibitors as new antivirals against influenza
Planz, O. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.008 · Cited by 106
“Because PI3K/AKT/mTOR, together with Raf/MEK/ ERK, plays a key role in the regulation of cell growth and differentiation (Carracedo and Pandolfi, 2008; Castellano and Downward, 2011), several proteins in the pathway are valuable targets for anticancer therapy, and some mTOR are licensed and administered in routine pra…”
BackgroundKRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10419-2 · Cited by 97
Soares, H. P., Ming, M., Mellon, M., Young, S. H., Han, L., Sinnet-Smith, J., & Rozengurt, E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0669 · Cited by 97
“The PI3K/mTOR pathway functions downstream of RAS (8), which is mutated in 90% of PDACs, and plays a key role in insulin/IGF receptor signaling.”
InfluentialWatkins, J. C., Howitt, B. E., Horowitz, N. S., Ritterhouse, L. L., Dong, F., MacConaill, L. E., Garcia, E. P., Lindeman, N. I., Lee, L. J., Berkowitz, R. S., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.187 · Cited by 97
Papadopoulos, K. P., Tabernero, J., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J., Shi, W., Egile, C., Ruiz-Soto, R., Laird, A. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 95
Chiosea, S. I., Thompson, L. D. �., Weinreb, I., Bauman, J. E., Mahaffey, A. L., Miller, C., Ferris, R. L., & Gooding, W. E. (2016) · Cancer · doi:10.1002/cncr.30179 · Cited by 100
“For instance, HRAS/PIK3CA cooperation is crucial to HRASinduced skin cancer formation.(35,36) In other solid tumors, PIK3CA mutations are believed to occur in invasive tumors, whereas upstream mutations in RAS genes occur at comparable rates at early and late stages, suggesting that PIK3CA mutation is a later event th…”
BackgroundGuidance of Cell Migration by Substrate Dimension
Chang, S., Guo, W.-H., Kim, Y., & Wang, Y.-L. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2012.12.001 · Cited by 108
“A possible explanation of the defect at the molecular level may be the ability of ras to activate the PI3 kinase (35), which is in turn involved in the formation of lamellipodia from filopodia on 2D surfaces (36).”
BackgroundCanté-Barrett, K., Spijkers-Hagelstein, J. A. P., Buijs-Gladdines, J. G. C. A. M., Uitdehaag, J. C. M., Smits, W. K., van der Zwet, J., Buijsman, R. C., Zaman, G. J. R., Pieters, R., & Meijerink, J. P. P. (2016) · Leukemia · doi:10.1038/leu.2016.83 · Cited by 94
Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers
Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., & Nussinov, R. (2016) · Biochemical Journal · doi:10.1042/bcj20160031 · Cited by 92
Miglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 98
Adhikari, H., & Counter, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05692-6 · Cited by 91
Martinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92
RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity
Kawasaki, J., Aegerter, S., Fevurly, R. D., Mammoto, A., Mammoto, T., Şahin, M., Mably, J. D., Fishman, S. J., & Chan, J. C.-Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67084 · Cited by 99
“Furthermore, RAS can also stimulate PI3K through direct interaction with the catalytic p110 α subunit (54–57).”
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2994 · Cited by 91
Mellor, P., Furber, L. A., Nyarko, J. N. K., & Anderson, D. H. (2011) · Biochemical Journal · doi:10.1042/bj20111164 · Cited by 109
Salgado, C. M., Basu, D., Nikiforova, M. N., Bauer, B. S., Johnson, D., Rundell, V. L. M., Grunwaldt, L. J., & Reyes‐Múgica, M. (2014) · Pediatric and Developmental Pathology · doi:10.2350/14-10-1566-oa.1 · Cited by 91
Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 103
“PI3K-AKT pathway Another established pathway is the PI3K/AKT pathway [92].”
BackgroundFeedback regulation of RTK signaling in development
Neben, C. L., Lo, M., Jura, N., & Klein, O. D. (2017) · Developmental Biology · doi:10.1016/j.ydbio.2017.10.017 · Cited by 91
KRAS G12C Mutations in NSCLC: From Target to Resistance
Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 82
AKT-independent PI3-K signaling in cancer – emerging role for SGK3
Hannan, R., Bruhn, Pearson, R., & Sheppard (2013) · Cancer Management and Research · doi:10.2147/cmar.s35178 · Cited by 83
“40,48 Class II PI3-K comprises three catalytic isoforms (C2 α , C2 β , and C2 γ ) which generate both phosphatidylinositol 3-phosphate (PI(3)P) and PI(3,4) P 2 , 49 and while PI(3)P localizes SGK3 to the endosome, it is the class I PI3-K that have shown to be associated with SGK3 activation.”
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.